What is the recommended treatment for hemochromatosis?

Treatment of Hemochromatosis

Phlebotomy is the first-line treatment for hemochromatosis and should be initiated immediately when serum ferritin is ≥300 µg/L in men or ≥200 µg/L in women, regardless of symptoms. 1

When to Start Treatment

Initiate therapeutic phlebotomy based on these thresholds:

• Men and postmenopausal women: transferrin saturation >50% AND ferritin >300 µg/L 1
• Premenopausal women: transferrin saturation >45% AND ferritin >200 µg/L 1
• Any patient with end-organ damage (liver disease, diabetes, cardiomyopathy, arthropathy) warrants immediate phlebotomy even if ferritin is below threshold 1
• Non-HFE hemochromatosis: confirmed iron overload on MRI or liver biopsy plus elevated transferrin saturation requires immediate treatment 1

A critical point: do not wait for symptoms before starting therapy—ferritin thresholds alone justify treatment. 1 Early diagnosis and treatment prevent cirrhosis, hepatocellular carcinoma, diabetes, and arthropathy. 2

Induction Phase Protocol

The goal is aggressive iron depletion to ferritin ≈50 µg/L: 3, 1

• Remove 400-500 mL per session scheduled weekly or every two weeks based on body weight and tolerance 1
• Check hemoglobin before each phlebotomy 3, 1
  • If hemoglobin <12 g/dL → reduce frequency or volume 3, 1
  • If hemoglobin <11 g/dL → pause treatment and reassess 3, 1
• Monitor ferritin after every 4 phlebotomies (approximately monthly) until it falls below 200 µg/L, then check every 1-2 sessions 3, 1
• Target ferritin: 50 µg/L 3, 1

The induction phase typically requires weekly or biweekly sessions until iron stores are depleted. 3

Maintenance Phase Protocol

Once target ferritin is achieved, switch to lifelong maintenance therapy: 3

• Frequency: individualized schedule of 2-6 phlebotomies per year (range: every 1-4 months) 3, 1
• Maintenance ferritin goal: 50-100 µg/L 3, 1
• Check hemoglobin before each session 3
• Monitor ferritin and transferrin saturation every 6 months 3, 1

Iron re-accumulation rates vary significantly—some patients need monthly maintenance while others require only 1-2 units annually. 1

Alternative Treatment Options

Erythrocytapheresis is a therapeutic option when available and may be preferred in selected cases: 3

• Causes fewer hemodynamic changes compared to phlebotomy 3
• Reduces the number of procedures and treatment duration during induction phase 3
• Returns valuable blood components 3
• Mild citrate reactions are more common 3
• Target ferritin: induction 50 µg/L, maintenance 50-100 µg/L 3

Iron chelation therapy (e.g., oral deferasirox) is second-line treatment only when phlebotomy is not possible, after careful risk-benefit assessment by a specialist due to adverse events. 3 It may be necessary in severe juvenile hemochromatosis, especially during induction. 3 Target ferritin is higher with chelation compared to phlebotomy. 3

Special Populations and Safety Considerations

Patients with advanced cardiac disease (arrhythmias or cardiomyopathy) face heightened risk of sudden death from rapid iron mobilization and should be managed in specialized centers; they may require mini-phlebotomies combined with deferoxamine. 1

Elderly patients may tolerate a more relaxed maintenance target (ferritin <200 µg/L for women, <300 µg/L for men) when aggressive depletion to 50 µg/L is poorly tolerated, though this is based on expert opinion rather than trial data. 1

Patients with advanced liver fibrosis should be included in hepatocellular carcinoma screening programs. 2

Essential Patient Counseling

Dietary modifications do not substitute for iron removal therapy: 3

• Avoid iron and vitamin C supplements 3, 1
• Avoid daily red meat consumption 3
• Avoid moderate to heavy alcohol intake 3
• Patients with advanced liver disease must abstain from alcohol completely 3
• Avoid raw/undercooked seafood and contact of wounds with seawater (risk of Vibrio vulnificus infection) 3
• Proton-pump inhibitors (when prescribed for other indications) can reduce phlebotomy need 3

Dietary iron restriction alone reduces absorption by only 2-4 mg/day compared with 200-250 mg removed per phlebotomy session. 1

Common Pitfalls to Avoid

• Do not perform liver biopsy in C282Y homozygotes with ferritin <1000 µg/L and normal liver enzymes—serum iron parameters are sufficient for diagnosis 1
• Discontinue frequent phlebotomy once ferritin reaches 50-100 µg/L to prevent overtreatment and iron deficiency 1
• If iron deficiency, anemia, or unexplained reduction in phlebotomy need develops during treatment, perform a complete workup for alternative causes 3
• Do not use vitamin C supplements during phlebotomy as they accelerate iron mobilization and increase toxicity 1

Patients identified with at-risk genotypes and increased transferrin saturation but without elevated ferritin may be encouraged to volunteer as regular blood donors, particularly if identified in early adulthood. 3